
FDA Leadership Changes Shake Up Gene Therapy Sector
Recent leadership changes at the FDA, including the removal of top officials overseeing cell and gene therapies, have created uncertainty in the biotech sector, impacting stock prices and raising questions about the future regulatory landscape for genetic medicines, especially following disagreements over drug approvals like Sarepta's Elevidys.